Loading…

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2002-12, Vol.42 (12), p.1352-1357
Main Authors: Martin, Paul D., Kemp, John, Dane, Aaron L., Warwick, Mike J., Schneck, Dennis W.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3
cites cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3
container_end_page 1357
container_issue 12
container_start_page 1352
container_title Journal of clinical pharmacology
container_volume 42
creator Martin, Paul D.
Kemp, John
Dane, Aaron L.
Warwick, Mike J.
Schneck, Dennis W.
description The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.
doi_str_mv 10.1177/0091270002042012008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_235858399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>257967071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</originalsourceid><addsrcrecordid>eNqNkF1v0zAUhi0EYmXwC5BQhMRl4PgjsXOJurEySpmmApeW6x7TrGk8bIet_x6HVuyGCyRLlqznOe_xS8hLCm8plfIdQEOZBAAGggFlAOoRmdCqYqWoQTwmk5EoR-SEPIvxBoDWoqJPyQllouaSw4RcL3xx7hzaVHhXXPs4_DIxmdT2he-LtMHiamPCzli_bXtMrY0jd9b-8PcZyWeGpkubffHNd0OfEEN8Tp4400V8cbxPydcP58vprJx_ufg4fT8vbUWbplwLK62zwEEgOMOMdAw5NhVS1sBq_BRXtmFNvVb1igq2drZSKBTUVHG0_JS8Psy9Df7ngDHpGz-EPkdqxitVKd40GeIHyAYfY0Cnb0O7M2GvKeixRv2PGrP16jh6WO1w_eAce8vAmyNgojWdC6a3bXzgBJesFmO8OHB3vku5m2033GHQmz-l5WgAkaPLHMrGZCjHp1FTR63tcP8_K-vL6dVMKJ7V8qC2MeH9X9WEra4ll5X-vrjQn5Z0cfl5OdeS_wZzdqbW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235858399</pqid></control><display><type>article</type><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</creator><creatorcontrib>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</creatorcontrib><description>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270002042012008</identifier><identifier>PMID: 12463730</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Area Under Curve ; Biological and medical sciences ; Cardiotonic agents ; Cardiovascular system ; Cross-Over Studies ; Digoxin - pharmacokinetics ; Double-Blind Method ; Drug Administration Schedule ; Drug Interactions ; Fluorobenzenes - blood ; Fluorobenzenes - pharmacology ; Fluorobenzenes - urine ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pyrimidines ; Rosuvastatin Calcium ; Sulfonamides ; Time Factors</subject><ispartof>Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357</ispartof><rights>2002 American College of Clinical Pharmacology</rights><rights>2002 SAGE Publications</rights><rights>2003 INIST-CNRS</rights><rights>Copyright SAGE PUBLICATIONS, INC. Dec 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</citedby><cites>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14372649$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12463730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Paul D.</creatorcontrib><creatorcontrib>Kemp, John</creatorcontrib><creatorcontrib>Dane, Aaron L.</creatorcontrib><creatorcontrib>Warwick, Mike J.</creatorcontrib><creatorcontrib>Schneck, Dennis W.</creatorcontrib><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cardiotonic agents</subject><subject>Cardiovascular system</subject><subject>Cross-Over Studies</subject><subject>Digoxin - pharmacokinetics</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Interactions</subject><subject>Fluorobenzenes - blood</subject><subject>Fluorobenzenes - pharmacology</subject><subject>Fluorobenzenes - urine</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidines</subject><subject>Rosuvastatin Calcium</subject><subject>Sulfonamides</subject><subject>Time Factors</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqNkF1v0zAUhi0EYmXwC5BQhMRl4PgjsXOJurEySpmmApeW6x7TrGk8bIet_x6HVuyGCyRLlqznOe_xS8hLCm8plfIdQEOZBAAGggFlAOoRmdCqYqWoQTwmk5EoR-SEPIvxBoDWoqJPyQllouaSw4RcL3xx7hzaVHhXXPs4_DIxmdT2he-LtMHiamPCzli_bXtMrY0jd9b-8PcZyWeGpkubffHNd0OfEEN8Tp4400V8cbxPydcP58vprJx_ufg4fT8vbUWbplwLK62zwEEgOMOMdAw5NhVS1sBq_BRXtmFNvVb1igq2drZSKBTUVHG0_JS8Psy9Df7ngDHpGz-EPkdqxitVKd40GeIHyAYfY0Cnb0O7M2GvKeixRv2PGrP16jh6WO1w_eAce8vAmyNgojWdC6a3bXzgBJesFmO8OHB3vku5m2033GHQmz-l5WgAkaPLHMrGZCjHp1FTR63tcP8_K-vL6dVMKJ7V8qC2MeH9X9WEra4ll5X-vrjQn5Z0cfl5OdeS_wZzdqbW</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Martin, Paul D.</creator><creator>Kemp, John</creator><creator>Dane, Aaron L.</creator><creator>Warwick, Mike J.</creator><creator>Schneck, Dennis W.</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Sage Science</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>200212</creationdate><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><author>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cardiotonic agents</topic><topic>Cardiovascular system</topic><topic>Cross-Over Studies</topic><topic>Digoxin - pharmacokinetics</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Interactions</topic><topic>Fluorobenzenes - blood</topic><topic>Fluorobenzenes - pharmacology</topic><topic>Fluorobenzenes - urine</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidines</topic><topic>Rosuvastatin Calcium</topic><topic>Sulfonamides</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Paul D.</creatorcontrib><creatorcontrib>Kemp, John</creatorcontrib><creatorcontrib>Dane, Aaron L.</creatorcontrib><creatorcontrib>Warwick, Mike J.</creatorcontrib><creatorcontrib>Schneck, Dennis W.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Paul D.</au><au>Kemp, John</au><au>Dane, Aaron L.</au><au>Warwick, Mike J.</au><au>Schneck, Dennis W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2002-12</date><risdate>2002</risdate><volume>42</volume><issue>12</issue><spage>1352</spage><epage>1357</epage><pages>1352-1357</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12463730</pmid><doi>10.1177/0091270002042012008</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_journals_235858399
source Wiley-Blackwell Read & Publish Collection
subjects Adolescent
Adult
Area Under Curve
Biological and medical sciences
Cardiotonic agents
Cardiovascular system
Cross-Over Studies
Digoxin - pharmacokinetics
Double-Blind Method
Drug Administration Schedule
Drug Interactions
Fluorobenzenes - blood
Fluorobenzenes - pharmacology
Fluorobenzenes - urine
General and cellular metabolism. Vitamins
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pyrimidines
Rosuvastatin Calcium
Sulfonamides
Time Factors
title No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A01%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20Effect%20of%20Rosuvastatin%20on%20the%20Pharmacokinetics%20of%20Digoxin%20in%20Healthy%20Volunteers&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Martin,%20Paul%20D.&rft.date=2002-12&rft.volume=42&rft.issue=12&rft.spage=1352&rft.epage=1357&rft.pages=1352-1357&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1177/0091270002042012008&rft_dat=%3Cproquest_cross%3E257967071%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=235858399&rft_id=info:pmid/12463730&rfr_iscdi=true